Literature DB >> 20053562

Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter.

Werner J Geldenhuys1, Vamshi K Manda, Rajendar K Mittapalli, Cornelis J Van der Schyf, Peter A Crooks, Linda P Dwoskin, David D Allen, Paul R Lockman.   

Abstract

A set of semi-rigid cyclic and acyclic bis-quaternary ammonium analogs, which were part of a drug discovery program aimed at identifying antagonists at neuronal nicotinic acetylcholine receptors, were investigated to determine structural requirements for affinity at the blood-brain barrier choline transporter (BBB CHT). This transporter may have utility as a drug delivery vector for cationic molecules to access the central nervous system. In the current study, a virtual screening model was developed to aid in rational drug design/ADME of cationic nicotinic antagonists as BBB CHT ligands. Four 3D-QSAR comparative molecular field analysis (CoMFA) models were built which could predict the BBB CHT affinity for a test set with an r(2) <0.5 and cross-validated q(2) of 0.60, suggesting good predictive capability for these models. These models will allow the rapid in silico screening of binding affinity at the BBB CHT of both known nicotinic receptor antagonists and virtual compound libraries with the goal of informing the design of brain bioavailable quaternary ammonium analogs that are high affinity selective nicotinic receptor antagonists. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20053562      PMCID: PMC2818856          DOI: 10.1016/j.bmcl.2009.12.079

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  43 in total

Review 1.  High-affinity choline transporter.

Authors:  Takashi Okuda; Tatsuya Haga
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

2.  Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Peter A Crooks; Joshua T Ayers; Rui Xu; Sangeetha P Sumithran; Vladimir P Grinevich; Lincoln H Wilkins; A Gabriela Deaciuc; David D Allen; Linda P Dwoskin
Journal:  Bioorg Med Chem Lett       Date:  2004-04-19       Impact factor: 2.823

3.  Inhibition of high-affinity choline transport in rat striatal synaptosomes by alkyl bisquaternary ammonium compounds.

Authors:  J T Holden; J Rossier; J C Beaujouan; P Guyenet; J Glowinski
Journal:  Mol Pharmacol       Date:  1975-01       Impact factor: 4.436

Review 4.  Molecular modeling of blood-brain barrier nutrient transporters: in silico basis for evaluation of potential drug delivery to the central nervous system.

Authors:  David D Allen; Werner J Geldenhuys
Journal:  Life Sci       Date:  2005-08-29       Impact factor: 5.037

Review 5.  In silico strategies for modeling membrane transporter function.

Authors:  Cheng Chang; Abhijit Ray; Peter Swaan
Journal:  Drug Discov Today       Date:  2005-05-01       Impact factor: 7.851

Review 6.  Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system.

Authors:  Q R Smith
Journal:  Pharm Biotechnol       Date:  1996

7.  Characterization of the blood-brain barrier choline transporter using the in situ rat brain perfusion technique.

Authors:  D D Allen; Q R Smith
Journal:  J Neurochem       Date:  2001-02       Impact factor: 5.372

Review 8.  Choline transport specificity in animal cells and tissues.

Authors:  J Lerner
Journal:  Comp Biochem Physiol C Comp Pharmacol Toxicol       Date:  1989

9.  Active transport of high-affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter.

Authors:  David D Allen; Paul R Lockman; Karen E Roder; Linda P Dwoskin; Peter A Crooks
Journal:  J Pharmacol Exp Ther       Date:  2003-03       Impact factor: 4.030

10.  Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration.

Authors:  N H Greig; S Genka; E M Daly; D J Sweeney; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

View more
  8 in total

1.  Identification of Novel Agents for the Treatment of Brain Metastases of Breast Cancer.

Authors:  Vinay K Venishetty; Werner J Geldenhuys; Tori B Terell-Hall; Jessica I G Griffith; Gregory R Sondag; Fayez F Safadi; Paul R Lockman
Journal:  Curr Cancer Drug Targets       Date:  2017       Impact factor: 3.428

2.  Bis-azaaromatic quaternary ammonium salts as ligands for the blood-brain barrier choline transporter.

Authors:  Guangrong Zheng; Zhenfa Zhang; Paul R Lockman; Werner J Geldenhuys; David D Allen; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2010-04-24       Impact factor: 2.823

Review 3.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

Review 4.  Molecular determinants of blood-brain barrier permeation.

Authors:  Werner J Geldenhuys; Afroz S Mohammad; Chris E Adkins; Paul R Lockman
Journal:  Ther Deliv       Date:  2015-08-25

5.  In silico predictive model to determine vector-mediated transport properties for the blood-brain barrier choline transporter.

Authors:  Sergey Shityakov; Carola Förster
Journal:  Adv Appl Bioinform Chem       Date:  2014-09-02

6.  Development of an a priori computational approach for brain uptake of compounds in an insect model system.

Authors:  Werner J Geldenhuys; Jeffrey R Bloomquist
Journal:  Bioorg Med Chem Lett       Date:  2021-03-10       Impact factor: 2.823

Review 7.  Blood Brain Barrier and Alzheimer's Disease: Similarity and Dissimilarity of Molecular Alerts.

Authors:  Alla P Toropova; Andrey A Toropov; Sanija Begum; Patnala G R Achary
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

8.  Characterizing the Access of Cholinergic Antagonists to Efferent Synapses in the Inner Ear.

Authors:  Choongheon Lee; Anjali K Sinha; Kenneth Henry; Anqi W Walbaum; Peter A Crooks; Joseph C Holt
Journal:  Front Neurosci       Date:  2021-12-14       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.